Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 10
Submit an article Journal homepage
2,433
Views
50
CrossRef citations to date
0
Altmetric
Original Research

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO

Nikolai SiebertDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany
,
Maxi ZumpeDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany
,
Madlen JüttnerDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, GermanyORCID Iconhttp://orcid.org/0000-0003-2040-0514
ORCID Icon,
Sascha Troschke-MeurerDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, GermanyORCID Iconhttp://orcid.org/0000-0002-6185-462X
ORCID Icon &
Holger N. LodeDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, GermanyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-1201-208X
ORCID Icon
Article: e1343775 | Received 10 May 2017, Accepted 12 Jun 2017, Published online: 28 Jul 2017

Citations (50)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Wayne L Furman. (2021) Monoclonal Antibody Therapies for High Risk Neuroblastoma. Biologics: Targets and Therapy 15, pages 205-219.
Read now
Soheila Shirinbak, Randall Y. Chan, Shilpa Shahani, Sakunthala Muthugounder, Rebekah Kennedy, Long T. Hung, G. Esteban Fernandez, Michael D. Hadjidaniel, Babak Moghimi, Michael A. Sheard, Alan L. Epstein, Muller Fabbri, Hiroyuki Shimada & Shahab Asgharzadeh. (2021) Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. OncoImmunology 10:1.
Read now
Nikolai Siebert, Maxi Zumpe, Leon von Lojewski, Sascha Troschke-Meurer, Madlen Marx & Holger N. Lode. (2020) Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO. OncoImmunology 9:1.
Read now

Articles from other publishers (47)

Xiang Chen, Ling-Juan Chen, Xiao-Fei Peng, Ling Deng, Yan Wang, Jiu-Jiang Li, Dong-Li Guo & Xiao-Hua Niu. (2024) Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations. Translational Oncology 40, pages 101851.
Crossref
Paul T Kennedy, Demetra Zannoupa, Meong Hi Son, Lekh N Dahal & John F Woolley. (2023) Neuroblastoma: an ongoing cold front for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 11:11, pages e007798.
Crossref
Seiichiro Inoue, Yuta Takeuchi, Yutaka Horiuchi, Takashi Murakami & Akio Odaka. (2023) CD69 on Tumor-Infiltrating Cells Correlates With Neuroblastoma Suppression by Simultaneous PD-1 and PD-L1 Blockade. Journal of Surgical Research 289, pages 190-201.
Crossref
Nikolai Siebert, Maxi Zumpe, Christian Heinrich Schwencke, Simon Biskupski, Sascha Troschke-Meurer, Justus Leopold, Alexander Zikoridse & Holger N. Lode. (2023) Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta. Cancers 15:13, pages 3317.
Crossref
Sascha Troschke-Meurer, Maxi Zumpe, Lena Meißner, Nikolai Siebert, Piotr Grabarczyk, Hannes Forkel, Claudia Maletzki, Sander Bekeschus & Holger N. Lode. (2023) Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models. Cancers 15:3, pages 904.
Crossref
Sara Marie Ivasko, Kathleen Anders, Laura Grunewald, Michael Launspach, Anika Klaus, Silke Schwiebert, Peter Ruf, Horst Lindhofer, Holger N. Lode, Lena Andersch, Johannes H. Schulte, Angelika Eggert, Patrick Hundsdoerfer, Annette Künkele & Felix Zirngibl. (2023) Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model. Frontiers in Immunology 13.
Crossref
Jung-Tung Hung & Alice L. Yu. 2023. Glycosignals in Cancer. Glycosignals in Cancer 215 238 .
Hetal N. Patel & Max J. Pachl. 2022. Pediatric Surgical Oncology. Pediatric Surgical Oncology 1 8 .
Xu Yang, Jixia Li & Jigang Yang. (2022) Promising Molecular Targets and Novel Therapeutic Approaches in Neuroblastoma. Current Pharmacology Reports 9:1, pages 43-58.
Crossref
Jingbo Qiao, Junquan Liu, Jillian C. Jacobson, Rachael A. Clark, Sora Lee, Li Liu, Zhiqiang An, Ningyan Zhang & Dai H. Chung. (2022) Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma. PLOS ONE 17:12, pages e0277956.
Crossref
Anup S. Pathania, Philip Prathipati, Swati P. Murakonda, Ajay B. Murakonda, Ankit Srivastava, Avadhesh, Siddappa N. Byrareddy, Don W. Coulter, Subash C. Gupta & Kishore B. Challagundla. (2022) Immune checkpoint molecules in neuroblastoma: A clinical perspective. Seminars in Cancer Biology 86, pages 247-258.
Crossref
Nikolai Siebert, Justus Leopold, Maxi Zumpe, Sascha Troschke-Meurer, Simon Biskupski, Alexander Zikoridse & Holger N. Lode. (2022) The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta. Cancers 14:19, pages 4842.
Crossref
Cristina Bottino, Mariella Della Chiesa, Stefania Sorrentino, Martina Morini, Chiara Vitale, Alessandra Dondero, Annalisa Tondo, Massimo Conte, Alberto Garaventa & Roberta Castriconi. (2022) Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants. Cancers 14:19, pages 4548.
Crossref
John Anderson, Robbie G. Majzner & Paul M. Sondel. (2022) Immunotherapy of Neuroblastoma: Facts and Hopes. Clinical Cancer Research 28:15, pages 3196-3206.
Crossref
Nicholas A. Maskalenko, Dmitry Zhigarev & Kerry S. Campbell. (2022) Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nature Reviews Drug Discovery 21:8, pages 559-577.
Crossref
Fabio Morandi & Irma Airoldi. (2022) HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies. International Journal of Molecular Sciences 23:6, pages 2925.
Crossref
Ombretta Melaiu, Valeria Lucarini, Roberto Giovannoni, Doriana Fruci & Federica Gemignani. (2022) News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology 79, pages 18-43.
Crossref
Nicholas J. Skertich, Fei Chu, Imad A. M. Tarhoni, Stephen Szajek, Jeffrey A. Borgia & Mary Beth Madonna. (2022) Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study. Cancers 14:3, pages 751.
Crossref
Jing-Yan Cheng, Jung-Tung Hung, Juway Lin, Fei-Yun Lo, Jing-Rong Huang, Shih-Pin Chiou, Ya-Hui Wang, Ruey-Jen Lin, Jen-Chine Wu, John Yu & Alice L. Yu. (2022) O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells. Frontiers in Immunology 12.
Crossref
Meriem Bahri, Sareetha Kailayangiri, Sarah Vermeulen, Natacha Galopin, Claudia Rossig, François Paris, Sophie Fougeray & Stéphane Birklé. (2021) SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells. Cancer Immunology, Immunotherapy 71:1, pages 71-83.
Crossref
Etienne C. Gozlan, Boris I. Chobrutskiy, Saif Zaman, Michelle Yeagley & George Blanck. (2021) Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells. Journal of Molecular Neuroscience 71:11, pages 2393-2404.
Crossref
Daria Lazic, Florian Kromp, Fikret Rifatbegovic, Peter Repiscak, Michael Kirr, Filip Mivalt, Florian Halbritter, Marie Bernkopf, Andrea Bileck, Marek Ussowicz, Inge M. Ambros, Peter F. Ambros, Christopher Gerner, Ruth Ladenstein, Christian Ostalecki & Sabine Taschner-Mandl. (2021) Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging. Cancers 13:17, pages 4311.
Crossref
Olga Nigro, Andrea Ferrari, Michela Casanova, Daniel Orbach, Amaury Leruste, Susanne A. Gatz, Didier Frappaz & Maura Massimino. (2021) Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy. Tumori Journal 107:4, pages 276-281.
Crossref
Cristina Bottino, Alessandra Dondero & Roberta Castriconi. (2021) Inhibitory axes impacting on the activity and fate of Innate Lymphoid Cells. Molecular Aspects of Medicine 80, pages 100985.
Crossref
M. V. Kiselevsky, I. V. Samoylenko, O. V. Zharkova, N. V. Ziganshina, A. A. Petkevich, S. M. Sitdikova, A. M. Suleymanova, G. B. Sagoyan, M. M. Efimova, K. I. Kirgizov & S. R. Varfolomeeva. (2021) Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors. Russian Journal of Pediatric Hematology and Oncology 8:2, pages 73-83.
Crossref
Miho Nakajima, Hong‐fen Guo, Sayed Shahabuddin Hoseini, Maya Suzuki, Hong Xu & Nai‐Kong V. Cheung. (2021) Potent antitumor effect of T cells armed with anti‐GD2 bispecific antibody. Pediatric Blood & Cancer 68:7.
Crossref
Irene Paraboschi, Laura Privitera, Gabriela Kramer-Marek, John Anderson & Stefano Giuliani. (2021) Novel Treatments and Technologies Applied to the Cure of Neuroblastoma. Children 8:6, pages 482.
Crossref
Aicha E. Quamine, Mallery R. Olsen, Monica M. Cho & Christian M. Capitini. (2021) Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors. Cancers 13:11, pages 2796.
Crossref
Holger N. Lode. (2021) Tumorimmuntherapie in der pädiatrischen OnkologieTumor immunotherapy in pediatric oncology. Der Onkologe 27:5, pages 470-477.
Crossref
Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan, Jacquelyn A. Hank, Ayse Batova, Wendy B. London, Sheena C. Tenney, Malcolm Smith, Barry L. Shulkin, Marguerite Parisi, Katherine K. Matthay, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Julie R. Park & Paul M. Sondel. (2021) Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research 27:8, pages 2179-2189.
Crossref
Judith Wienke, Miranda P. Dierselhuis, Godelieve A.M. Tytgat, Annette Künkele, Stefan Nierkens & Jan J. Molenaar. (2021) The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology. European Journal of Cancer 144, pages 123-150.
Crossref
Esther Coronado, Yania Yañez, Enrique Vidal, Luis Rubio, Francisco Vera‐Sempere, Antonio José Cañada‐Martínez, Joaquín Panadero, Adela Cañete, Ruth Ladenstein, Victoria Castel & Jaime Font de Mora. (2021) Intratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targets. Molecular Oncology 15:2, pages 364-380.
Crossref
T. V. Shamanskaya, N. A. Andreeva, D. T. Utalieva & D. Yu. Kachanov. (2020) Anti-GD2 immunotherapy with the chimeric antibody ch14.18 for high-risk neuroblastoma. Pediatric Hematology/Oncology and Immunopathology 19:3, pages 173-178.
Crossref
Seiichiro Inoue, Yutaka Horiuchi, Yumiko Setoyama, Yuta Takeuchi, Yoshifumi Beck, Takashi Murakami & Akio Odaka. (2020) Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma. Journal of Surgical Research 253, pages 201-213.
Crossref
Giuseppe Giglia, Giuditta Gambino & Pierangelo Sardo. (2020) Through Predictive Personalized Medicine. Brain Sciences 10:9, pages 594.
Crossref
Jeong A. Park & Nai-Kong V. Cheung. (2020) Targets and Antibody Formats for Immunotherapy of Neuroblastoma. Journal of Clinical Oncology 38:16, pages 1836-1848.
Crossref
Karoline Ehlert, Ina Hansjuergens, Andreas Zinke, Sylke Otto, Nikolai Siebert, Guenter Henze & Holger Lode. (2020) Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma. Journal for ImmunoTherapy of Cancer 8:1, pages e000540.
Crossref
Andrew D.J. Pearson, Claudia Rossig, Giovanni Lesa, Scott J. Diede, Susan Weiner, John Anderson, Juliet Gray, Birgit Geoerger, Veronique Minard-Colin, Lynley V. Marshall, Malcolm Smith, Paul Sondel, Marcis Bajars, Claudia Baldazzi, Elly Barry, Sam Blackman, Patricia Blanc, Renaud Capdeville, Hubert Caron, Peter D. Cole, Jorge Camarero Jiménez, Pierre Demolis, Martha Donoghue, Mabrouck Elgadi, Thomas Gajewski, Sara Galluzzo, Robert IlariaJr.Jr., Alessandro Jenkner, Dominik Karres, Mark Kieran, Franca Ligas, Israel Lowy, Michael Meyers, Corina Oprea, Vijay G.R. Peddareddigari, Jaroslav Sterba, Paul K. Stockman, Peter Suenaert, Uri Tabori, Cornelis van Tilburg, Todd Yancey, Brenda Weigel, Koenraad Norga, Gregory Reaman & Gilles Vassal. (2020) ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. European Journal of Cancer 127, pages 52-66.
Crossref
Celina L. Szanto, Annelisa M. Cornel, Saskia V. Vijver & Stefan Nierkens. (2020) Monitoring Immune Responses in Neuroblastoma Patients during Therapy. Cancers 12:2, pages 519.
Crossref
Kimberly J. Ornell & Jeannine M. Coburn. (2019) Developing preclinical models of neuroblastoma: driving therapeutic testing. BMC Biomedical Engineering 1:1.
Crossref
Julia Moreno-Vicente, Stephen A. Beers & Juliet C. Gray. (2019) PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. Cancer Letters 457, pages 74-85.
Crossref
Parnian Jabbari, Sara Hanaei & Nima Rezaei. (2019) State of the art in immunotherapy of neuroblastoma. Immunotherapy 11:9, pages 831-850.
Crossref
Colin G. Graydon, Allison L. Balasko & Keith R. Fowke. (2019) Roles, function and relevance of LAG3 in HIV infection. PLOS Pathogens 15:1, pages e1007429.
Crossref
Anupa Kudva & Shakeel Modak. 2019. Neuroblastoma. Neuroblastoma 147 173 .
Madlen Marx, Maxi Zumpe, Sascha Troschke-Meurer, Diana Shah, Holger N. Lode & Nikolai Siebert. (2018) Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice. PLOS ONE 13:11, pages e0207320.
Crossref
Fabio Morandi, Francesco Frassoni, Mirco Ponzoni & Chiara Brignole. (2018) Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. Journal of Immunology Research 2018, pages 1-12.
Crossref
John Inge Johnsen, Cecilia Dyberg, Susanne Fransson & Malin Wickström. (2018) Molecular mechanisms and therapeutic targets in neuroblastoma. Pharmacological Research 131, pages 164-176.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.